RxDoctor Payments Data

Martin Lugo Fagundo, MD

Internal Medicine · San Juan, PRNPI 1316944549

Payments from drug & device makers

$414in general payments, 2019–2025

Across 16 payments — averaging $25.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$104
  • AbbVie$100
  • Johnson & Johnson$74
  • PBG Puerto Rico LLC$39
  • Boehringer Ingelheim$37
  • Novo Nordisk$25
  • plus $35 from 2 others

What the payments were for

  • Food & beverage$414100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$414 in reported general payments places this provider in the 40th percentile of 1,043 internal medicine providers in Puerto Rico.

See all internal medicine providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$15,607
Medicare patients
85
Services billed
343

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol23$23,298
EliquisApixaban26$21,629
XareltoRivaroxaban11$7,520
SynthroidLevothyroxine Sodium34$3,471
Metoprolol Succinate42$841
Atorvastatin Calcium85$815
Pantoprazole Sodium47$671
Gabapentin44$611
Amiodarone Hcl15$604
Levothyroxine Sodium33$597
Losartan Potassium49$579
Finasteride21$450
Tamsulosin Hcl29$403
Simvastatin43$356
Carvedilol36$312

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$23$23,29823 claims
Johnson & JohnsonXarelto$74$7,52011 claims
AbbVieSynthroid$100$3,47134 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,043 internal medicine providers in Puerto Rico.

Other internal medicine in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →